Skip to main content
SpringerLink
Log in

Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

A prospective, open-labelled, multicentre 6-month study was designed to assess three categories that have high impact on Health-Related Quality of Life (HR-QoL). These categories were: satisfaction, preference and drug tolerability in postmenopausal patients with osteoporosis in Croatia, at first treated with weekly oral bisphosphonates, followed by monthly oral ibandronate. Three hundred eighty-five postmenopausal women who were treated with one of the weekly bisphosphonates for at least 6 months were included into the study and after they had signed written informed consent, the therapy was changed to monthly ibandronate. Satisfaction with the treatment was assessed with the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q). Patients completed OPSAT-Q at the baseline visit before the change of therapy (visit 1) and 6 months after the change of therapy (visit 2). Following 6 months ibandronate therapy, the values in all four domains of the OPSAT-Q (convenience, confidence with daily activities, overall satisfaction, side effects) as well as in the Composite Satisfaction Score were higher in visit 2 (p < 0.001). Values in subjects enrolled into the patient assistance programme did not differ significantly from the values in subjects that were not (p = 0.399) except for the domain convenience (p = 0.026). This study demonstrates significantly higher satisfaction in patients who switched from the weekly bisphosphonate therapy regimen to monthly ibandronate in all observed aspects of treatment. Patients expressed preference for monthly bisphosphonate (ibandronate) in comparison with weekly bisphosphonates and found it to be a more convenient method of treatment. At the time of study, however, it was not known that the anti-fracture effect of ibandronate was smaller for hip fractures than with other bisphosphonates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399–428

    Article  PubMed  CAS  Google Scholar 

  2. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155

    Article  PubMed  Google Scholar 

  3. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24(1):37–55

    Article  PubMed  CAS  Google Scholar 

  4. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17(11):1638–1644

    Article  PubMed  CAS  Google Scholar 

  5. Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG (2008) Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 30:605–621

    Article  PubMed  CAS  Google Scholar 

  6. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903

    Article  PubMed  CAS  Google Scholar 

  7. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310

    Article  PubMed  CAS  Google Scholar 

  8. Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M (2009) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 28:321–326

    Article  PubMed  Google Scholar 

  9. Grazio S, Babic-Naglic D, Kehler T, Curkovic B (2008) Persistence of weekly alendronate: a real-world study in Croatia. Clin Rheumatol 27(5):651–653

    Article  PubMed  Google Scholar 

  10. Cook DJ, Guyatt GH, Adachi JD, Clifton J, Griffith LE, Epstein RS, Juniper EF (1993) Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 36:750–756

    Article  PubMed  CAS  Google Scholar 

  11. Martin AR, Sornay-Rendu E, Chandler JM, Duboeuf F, Girman CJ, Delmas PD (2002) The impact of osteoporosis on quality-of-life: the Ofely Cohort. Bone 31:32–36

    Article  PubMed  CAS  Google Scholar 

  12. de Oliveira FN, Arthuso M, da Silva R, Pedro AO, Neto AM, Costa-Paiva L (2009) Quality of life in women with postmenopausal osteoporosis: correlation between QUALEFFO 41 and SF-36. Maturitas 62:85–90

    Article  Google Scholar 

  13. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619

    Article  PubMed  CAS  Google Scholar 

  14. Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755–763

    Article  PubMed  CAS  Google Scholar 

  15. Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R (2009) Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt). doi:10.1089/jwh.2008.1064

  16. Lambrinoudaki I, Christodoulakos G, Botsis D (2006) Bisphosphonates. Ann N Y Acad Sci 1092:397–402

    Article  PubMed  CAS  Google Scholar 

  17. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 44(5):758–765

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

TV has received lectures fees from Aventis, Eli Lilly and Roche. DK has received lectures fees from Merck Sharp & Dohme, Roche and Eli Lilly. BM has received lectures fees from Roche. ŽCO has received lectures fees from Merck Sharp & Dohme, Elli Lilly and Roche. MK has received lectures fees from Merck Sharp & Dohme, Aventis, Roche and Servier. PL, JA, MG, ŠM, TN, DC, GT, TD, ZJ, FG, TP, MB, FDž, MSU, MK, MR, MV, ŽK, MP, ER and LJL have no disclosures.

Author information

Authors and Affiliations

  1. Department of Rehabilitation Medicine and Rheumatology, University Hospital Split, School of Medicine in Split, Marmontova 4, 21000, Split, Croatia

    Tonko Vlak & Jure Aljinović

  2. Department of Endocrinology, University Hospital Zagreb, School of Medicine in Zagreb, Zagreb, Croatia

    Darko Kaštelan, Tina Dušek, Feđa Džubur & Mirko Koršić

  3. Outpatient Clinic for Gynaecology Lozo, Zadar, Croatia

    Petar Lozo

  4. Department of Internal Medicine, County Hospital Čakovec, Čakovec, Croatia

    Marina Gradišer

  5. Health Medical Centre for Physical Medicine and Rehabilitation, Jastrebarsko, Croatia

    Šime Mijić

  6. University Clinic of Traumatology, School of Medicine in Zagreb, Zagreb, Croatia

    Tatjana Nikolić, Dolores Car & Gordana Tajšić

  7. Department of Internal Medicine, General Hospital Dr. Josip Benčević, Slavonski Brod, Croatia

    Blaženka Miškić

  8. Department of Rheumatology, Physical Medicine and Rehabilitation, University Hospital “Sestre Milosrdnice”, School of Medicine in Zagreb, Zagreb, Croatia

    Zrinka Jajić & Frane Grubišić

  9. University Clinic for Diabetes, Endocrinology and Metabolic Diseases “Vuk Vrhovac”, School of Medicine in Zagreb, Zagreb, Croatia

    Tamara Poljičanin

  10. Department of Endocrinology, Diabetes and Metabolic Disorders, General Hospital “Sv. Duh”, School of Medicine in Zagreb, Zagreb, Croatia

    Miro Bakula

  11. General Hospital Šibenik, Šibenik, Croatia

    Matilda Strižak-Ujević

  12. Department of Physical Medicine and Rehabilitation, University Hospital Osijek, School of Medicine in Osijek, Osijek, Croatia

    Mira Kadojić

  13. Department of Endocrinology, Diabetes and Metabolism, University Hospital Split, School of Medicine in Split, Split, Croatia

    Maja Radman

  14. School of Medicine in Zagreb, University of Zagreb, Zagreb, Croatia

    Maja Vugrinec, Željka Kuster & Marijeta Pekez

  15. Department of Physical and Rehabilitation Medicine, University Hospital Rijeka, School of Medicine in Rijeka, Rijeka, Croatia

    Endi Radović

  16. Special Hospital for Orthopaedics, Biograd, Croatia

    Ljubica Labar

  17. Department of Endocrinology, University Hospital Rijeka, School of Medicine in Rijeka, Rijeka, Croatia

    Željka Crnčević-Orlić

Authors
  1. Tonko Vlak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darko Kaštelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petar Lozo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jure Aljinović
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marina Gradišer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Šime Mijić
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatjana Nikolić
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Blaženka Miškić
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dolores Car
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gordana Tajšić
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tina Dušek
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zrinka Jajić
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Frane Grubišić
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Tamara Poljičanin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Miro Bakula
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Feđa Džubur
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Matilda Strižak-Ujević
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Mira Kadojić
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Maja Radman
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Maja Vugrinec
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Željka Kuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Marijeta Pekez
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Endi Radović
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Ljubica Labar
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Željka Crnčević-Orlić
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Mirko Koršić
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tonko Vlak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vlak, T., Kaštelan, D., Lozo, P. et al. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. Clin Rheumatol 30, 1549–1554 (2011). https://doi.org/10.1007/s10067-011-1858-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1858-3

Keywords

Search

Navigation